Powering the Immune System
to Transform Lives
Vir leverages the immense potential of the immune system to address critical unmet medical needs and improve patient outcomes
Our experts at Vir have broken ground in immunology, demonstrating our ability to discover, engineer, and develop antibody-based medicines for two of the greatest health challenges of our time: COVID-19 and Ebola.
Vir’s pipeline is built on two technology platforms which enable us to rapidly identify, optimize, and advance candidates from concepts to the clinic: our next-generation antibody platform and our PRO-XTENTM protease-releasable masking platform.
We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in infectious diseases, with leading programs in hepatitis delta and hepatitis B, are complemented by strategic programs in oncology. Every day, we work with the utmost urgency to deliver potentially transformative options for patients.
“At Vir we engineer antibodies into powerful, impactful medicines, and deliver them to patients who are waiting - fast. We are fueled by the company’s deep capabilities in knowledge of immunology, and our ability to apply that knowledge to power the human immune system to fight disease and transform patients’ lives for the better.”
– CEO Marianne De Backer, M.Sc., Ph.D., MBA
An experienced leadership team
We have an industry-leading management team and Board of Directors with a proven track record of progressing product candidates from early-stage research through clinical development, and worldwide regulatory approval and commercialization.
Join Us in Our Mission to Deliver Transformative Medicines
We offer the opportunity to do challenging, rewarding work as part of our world class teams in the U.S. and Europe. If you share our goal of addressing the unmet needs of patients around the world, please visit our careers page for open positions.